Histologic grade and cd44 are independent predictors of axillary lymph node invasion in early (t1) breast cancer

Tumor Biology

Volumn 20, Issue 6, 1999, Pages 319-330

  Schneider, J ^a,b   Pollan M ^c   Ruibal, A ^a   Jimenez E ^b   Lucas, A R ^a   Nunez M I ^a   Sanchez J ^a,d   Tejerina, A ^a  

^a Fund Tejerina Ctro Patol Mama   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Breast cancer; N1; Node invasion; Prognostic factors; T1

Indexed keywords

HERMES ANTIGEN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CONSERVATIVE TREATMENT; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032719303     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030096     Document Type: Article

References (48)

1. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 27,740 breast cancer cases. Cancer 1989;63:181-187.
2. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellmann S: Pathological prognostic factors in stage 1 (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7:1239-1251.
3. Fisher B, Slack NH, Bross IDJ: Cancer of the breast: Size of the neoplasm and prognosis. Cancer 1969; 24:1071-1081.
4. Cady B, Stone MD, Schuler JG, Thakur R, Waner MA, Lavin PT: The new era in breast cancer. Invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996;131:301-308.
5. Silverstein MJ, Gierson DE, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P: Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994; 73:664-667.
6. Schneider J, Romero H: Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients. Anticancer Res 1995;15: 1117-1122.
7. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M: P glycoprotein expression in treated and untreated breast cancer. Br J Cancer 1989;60:815-818.
8. Schneider J, Rubio MP, Barbazán MJ, Rodríguez-Escudero FJ, Seizinger BS, Castresana JS: P-glycoprotein, HER-2/neu and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994;86: 850-855.
9. Schneider J, Romero H, Ruiz R, Centeno MM, Rodriguez-Escudero FJ: nm23 expression in advanced and borderline ovarian carcinoma. Anticancer Res 1996;16:1197-1202.
10. Cody HS: Sentinel lymph node mapping in breast cancer. Oncology (Huntingt) 1999;13:25-34.
11. American College of Surgeons Commission on Cancer: Final Report on Long-Term Patient Care Evaluation Study for Carcinoma of the Female Breast. ACS Bull 1979, pp 1-42.
12. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
13. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 1957;11: 359-377.
14. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA: Interobserver reproducibility of histopathological features in stage II breast cancer: An ECOG study. Breast Cancer Res Treat 1985;5:3-10.
15. Dalton LW, Page DL, Dupont WD: Histologic grading of breast carcinoma. A reproducibility study. Cancer 1994;73:2765-2770.
16. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C: Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol 1995;26:873-879.
17. Henson DE, Ries L: Relationship among outcome, stage of disease and histologic grade in 22,616 cases of breast cancer. Cancer 1991;68: 2142-2149.
18. Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer 1994;74(suppl): 381-400.
19. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-204.
20. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS: Association of low nm23 RNA levels in primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 1989;49:5185-5190.
21. Hennessy C, Henry JA, May FE, Westley BR, Angus B, Lennard TW: Expression of the antimetastatic gene nm23 in human breast cancer: An association with good prognosis. J Natl Cancer Inst 1991;83:281-285.
22. Sauer T, Furu I, Beraki K, Jebsen PW, Ormerod E, Naess O: nm23 protein expression in fine-needle aspirates from breast carcinoma: Inverse correlation with cytologic grading, lymph node status, and ploidy. Cancer 1998;84:109-114.
23. Sastre-Garau X, Lacombe ML, Jouve M, Veron M, Magdalenat H: Nucleoside diphosphate kinase/ NM23 expression in breast cancer: Lack of correlation with lymphnode metastasis. Int J Cancer 1992; 50:533-538.
24. Goodall RJ, Dawkins HJ, Robbins PD, Hahnel E, Sarna M, Hahnel R, Papadimitriou JM, Harvey JM, Sterret GF: Evaluation of the expression levels of nm23-H1 mRNA primary breast cancer, benign breast disease, axillary lymph nodes and normal breast tissue. Pathology 1994;26:423-428.
25. Sawan A, Lascu U, Veron M, Anderson JJ, Wright G, Horne CH, Angus B: NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: An immunohistochemical study. J Pathol 1994;172:27-34.
26. Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ, Silcocks PB: nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993;85: 727-731.
27. Albertazzi E, Cajone F, Leone BE, Naguib RN, Lakshmi MS, Sherbet GV: Expression of metastasis-associated genes h-mtsl (S100A4) and nm23 in carcinoma of breast is related to disease progression. DNA Cell Biol 1998;1:335-342.
28. Heimann R, Ferguson DJ, Hellman S: The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res 1998;8:2766-2771.
29. Yamaguchi A, Ding K, Machara M, Goi T, Nakagawara G: Expression of nm23-H1 gene and sialyl Lewis X antigen in breast cancer. Oncology 1998;55:357-362.
30. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1994;84:845-855.
31. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
32. Révillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
33. Vielh P, Chevillard S, Mosseri V, Donatini B, Magdalenat H: Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol 1990;94:681-686.
34. Lawry J, Giri D, Rogers K, Duncan JL: The value of assessing cell proliferation in breast cancer. J Microsc 1990;159:265-275.
35. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla Palma P, Barbareschi M: PCNA and Ki67 expression in breast carcinoma: Correlations with clinical and biological variables. J Clin Pathol 1992;45:416-419.
36. Barnard NJ, Hall PA, Lemoine NR, Kadar N: Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987;152: 287-295.
37. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI: Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 1989; 59:943-947.
38. Locker AP, Birrell K, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO: Ki67 immunoreactivity in breast carcinoma: Relationships to prognostic variables and short-term survival. Eur J Surg Oncol 1992;18:224-229.
39. Mink D, von Tongelen B, Villena-Heinsen C, Heiss C, Schmidt W: Breast cancer and prognostic factors. Tumor size, degree of differentiation, proliferation kinetics and expression of steroid hormone receptors. Eur J Gynaecol Oncol 1994; 15:424-436.
40. Naot D, Sionov RV, Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319.
41. Lyzak JS, Yaremko ML, Recant W, Baunoch DA, Joseph L: Role of CD44 in nonpalpable T1a and T1b breast cancer. Hum Pathol 1997;28: 772-778.
42. Tempfer C, Losch A, Heinzl H, Hausler G, Hanzal E, KLolbl H, Breitenecker G, Kainz C: Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996; 32A:2023-2025.
43. Fuller KJ, Issels RD, Slosman DO, et al: Cancer and the heat shock response. Eur J Cancer 1994;30A: 1884-1891.
44. Brodsky JL: Post-translational protein translocation: Not all hsp70s are created equal. Trends Biochem Sci 1996;21:122-126.
45. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL: Heat-shock protein hsp70 in patients with axillary lymph node-negative breast cancer: Prognostic implications. J Natl Cancer Inst 1993;85:570-574.
46. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA: Biological and clinical implications of heat shock protein 27000 (Hsp27): A review. J Natl Cancer Inst 1993;85:1158-1570.
47. Schneider J, Jimenez E, Marenbach K, Marx D, Meden H: Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res 1998;18:2967-2972.
48. Storm FK, Mahvi DM, Gilchrist KW: Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 1996;3:570-573.